1-Chloro-2-(2,2-Dichloro-1-(4-Chlorophenyl)Ethyl)Benzene 1-氯-2-(2,2-二氯-1-(4-氯苯基)乙基)苯
CAS 53-19-0 MFCD00000850
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Alphabetical Index of Analytical Standards, Method and Regulation Specific, Analytical Standards, Analytical/Chromatography, Bioactive Small Molecules, Cell Biology, D, D-DIF, DA - DH, Oeko-Tex Standard 100, Pesticides
- {SNA} Bioactive Small Molecule Alphabetical Index, C-CH, 生物活性小分子, 细胞生物学
- {SNA} Bioactive Small Molecules, C-CH, Cell Biology
产品应用
- An adrenal cytotoxic agent.
相关文献及参考
- Merck:13,6237 / 13,6237 Beilstein: 5,IV,1883
安全信息
GHS Symbol
- P201 Obtain special instructions before use. 使用前获取专门指示。
- P202 Do not handle until all safety precautions have been read and understood. 已阅读并理解所有的安全预防措施之前,切勿操作。
- P260 Do not breathe dust/fume/gas/mist/vapours/spray. 不要吸入粉尘/烟/气体/烟雾/蒸汽/喷雾。
- P261 Avoid breathing dust/fume/gas/mist/vapours/spray. 避免吸入粉尘/烟/气体/烟雾/蒸汽/喷雾。
- P264 Wash hands thoroughly after handling. 处理后要彻底洗净双手。
- P270 Do not eat, drink or smoke when using this product. 使用本产品时不要吃东西,喝水或吸烟。
- P271 Use only outdoors or in a well-ventilated area.? 只能在室外或通风良好的地方使用。
- P280 Wear protective gloves/protective clothing/eye protection/face protection. 戴防护手套/防护服/眼睛的保护物/面部保护物。
- P281 Use personal protective equipment as required. 使用所需的个人防护装备。
- P304+P340
- P307+P311
- P308+P313
- P312 Call a POISON CENTER or doctor/physician if you feel unwell. 如果你感觉不适,呼叫解毒中心或医生/医师。
- P314 Get medical advice/attention if you feel unwell. 获取医疗咨询/就医,如果你觉得不舒服
- P321 Specific treatment (see … on this label). 具体治疗(见本标签上的)。
- P403+P233
- P405 Store locked up. 上锁保管。
- P501 Dispose of contents/container to..… 处理内容物/容器.....
- H351 Suspected of causing cancer 怀疑致癌
- S36/37 Wear suitable protective clothing and gloves 穿戴适当的防护服和手套;
- R40 Limited evidence of a carcinogenic effect 有限证据表明其致癌作用
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2500 mg/kg/7W-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - lymphoma, including Hodgkin's disease Skin and Appendages - tumors REFERENCE : CANCAR Cancer (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1948- Volume(issue)/page/year: 40,1935,1977
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 9750 mg/kg/26W-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Lungs, Thorax, or Respiration - tumors Blood - lymphoma, including Hodgkin's disease REFERENCE : CANCAR Cancer (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1948- Volume(issue)/page/year: 40,1935,1977
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 10 gm/kg/52W-C TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Reproductive - Tumorigenic effects - testicular tumors REFERENCE : BAFEAG Bulletin de l'Association Francaise pour l'Etude du Cancer. (Paris, France) V.1-52, 1908-65. For publisher information, see BUCABS. Volume(issue)/page/year: 52,89,1965
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 17 gm/kg/35W TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) REFERENCE : CANCAR Cancer (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1948- Volume(issue)/page/year: 42,2177,1978
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 11 gm/kg/15W TOXIC EFFECTS : Vascular - BP lowering not characterized in autonomic section Blood - normocytic anemia Blood - pigmented or nucleated red blood cells REFERENCE : CANCAR Cancer (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1948- Volume(is
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 14 gm/kg/22W TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea Gastrointestinal - nausea or vomiting REFERENCE : CANCAR Cancer (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1948- Volume(issue)/page/year: 42,2177,1978
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 800 mg/kg/4D TOXIC EFFECTS : Skin and Appendages - dermatitis, other (after systemic exposure) REFERENCE : CANCAR Cancer (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1948- Volume(issue)/page/year: 42,2177,1978
TYPE OF TEST : Cytogenetic analysis TEST SYSTEM : Rodent - rat Cells - not otherwise specified DOSE/DURATION : 10 ug/L REFERENCE : 34LXAP "Insecticide Biochemistry and Physiology," Wilkinson, C.F., ed., New York, Plenum Pub. Corp., 1976 Volume(issue)/page/year: -,555,1976
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE : 900 mg/kg SEX/DURATION : female 6-14 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) REFERENCE : NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information. Volume(issue)/page/year: PB223-160
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE : 16 gm/kg SEX/DURATION : male 15 week(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct REFERENCE : JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 25,463,1987
TYPE OF TEST : TDLo - Lowest published toxi
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE : 250 mg/kg SEX/DURATION : female 15-19 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Specific Developmental Abnormalities - urogenital system REFERENCE : BNEOBV Biology of the Neonate. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.15- 1970- Volume(issue)/page/year: 26,283,1975
其他信息
- 药理作用:米托坦结构与杀虫药滴滴涕(DDT)和DDD相似,它能选择性地使肾上腺皮质束状带及网状带细胞萎缩、坏死,但不影响球状带,故醛固酮分泌不受影响。用药后血、尿中氢化可的松及其代谢物迅速减少,体内肾上腺皮质激素及其代谢产物水平迅速下降,适用于治疗无法手术的、功能性和非功能性肾上腺皮质癌、肾上腺瘤、肾上腺增生引起的枯氏综合征、肾上腺皮质增生、皮质癌术后辅助治疗以及肿瘤所致的皮质醇增多症。 口服约40%由胃肠道吸收,其余60%以原型随粪便排出。每日5~10g,血药浓度可达10~90μg/ml,代谢物浓度30~50μg/ml。停药6~9周后,血浆中仍可测到邻氯烷。米托坦脂溶性高,主要储存于脂肪中。从尿中排出的水溶性代谢物约占给药量的25%。
- MOL 文件:53-19-0.mol
- 可燃性危险特性:热分解排出有毒氯化物烟雾
- 类别:有毒物质
- Sigma Aldrich:53-19-0(sigmaaldrich)
- 图谱信息:米托坦(53-19-0)红外图谱(IR2) 米托坦(53-19-0)核磁图( 13 CNMR) 米托坦(53-19-0)红外图谱(IR1) 米托坦(53-19-0)核磁图( 1 HNMR) 米托坦(53-19-0)Raman光谱 米托坦(53-19-0)质谱(MS)
- 毒性分级:中毒
- 储运特性:库房低温通风干燥
- MSDS 信息:2,2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane(53-19-0).msds
- 急性毒性:口服-大鼠 LD50: >; 5000 毫克/公斤; 口服-小鼠 LD50: >; 4000 毫克/公斤
- Mitotane 是一种抗肿瘤药,用于治疗肾上腺皮质癌。
- 溶于乙醇和四氯化碳。
- 用途一:抗肿瘤药,用于治疗肾上腺皮质癌。
- 方法一:由邻溴氯苯(见05820)经下述步骤制得。
- 灭火剂:水,二氧化碳, 泡沫, 干粉
- 上游原料:2-溴氯苯
- 用途二:抗肿瘤药,用于治疗肾上腺皮质癌